When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?
Author(s): Beda M, Basso U, Ghiotto C, Monfardini S Affiliation(s): Department of Medical Oncology, Istituto Oncologico Veneto-IOV, Padua, Italy. m.beda@libero.it Publication date & source: 2007-09, Tumori., 93(5):491-2. Publication type: Case Reports We report the case of a woman with HER2-positive metastatic breast cancer who achieved prolonged complete remission of multiple liver metastases after treatment with weekly trastuzumab plus paclitaxel but relapsed in the brain soon after stopping trastuzumab maintenance therapy which had been prosecuted for almost three years. In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable.
Related Questions
- How long should I continue therapy with Herceptin in the treatment of HER2-positive metastatic breast cancer?
- do patients with a complete pathological response differ from those with residual tumour in the breast?
- Can high-frequency ultrasound predict metastatic lymph nodes in patients with invasive breast cancer?
